



TCR² Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

Cambridge, MA, November 9, 2017 – TCR² Therapeutics Inc. announced today that its Chief Executive Officer, Garry E. Menzel, Ph.D., will present a company overview at the Jefferies 2017 Global Healthcare Conference on Wednesday, November 15, 2017 at 10:40am GMT/5:40am EST. The event will be held in London, UK at the Waldorf Hilton.

About TCR² Therapeutics

TCR² Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors that utilize the full signaling power of complete T cell receptors (TCR). TCR² has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to elicit rapid killing of cancer cells with persistence and low cytokine release. The company has demonstrated superior activity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead program TC-210 into the clinic in 2018. TCR² was founded in 2015 by Dr. Patrick Baeuerle and backed with a \$44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.

Media Contact:

Kathy Vincent
(310) 403-8951
kathy@kathyvincent.com

###